Core Viewpoint - Ji'an Medical's stock price has shown fluctuations, with a slight increase of 2.02% on September 8, 2023, while the company faces a decline in revenue but an increase in net profit year-on-year [1][2]. Company Overview - Ji'an Medical, established on August 22, 1995, and listed on June 10, 2010, is located in Tianjin and specializes in the research, production, and sales of home medical health electronic products [1]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [1]. Financial Performance - For the first half of 2025, Ji'an Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to shareholders reached 920 million yuan, reflecting a year-on-year increase of 52.91% [2]. - Cumulatively, the company has distributed 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed over the past three years [3]. Shareholder Information - As of August 10, 2025, the number of Ji'an Medical shareholders increased to 73,000, with an average of 6,491 circulating shares per person, a decrease of 2.19% from the previous period [2]. - The top ten circulating shareholders include notable ETFs, with the Huabao Zhongzheng Medical ETF holding 10.9885 million shares, a decrease of 1.836 million shares from the previous period [3].

Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company was listed on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing industry [1]. Stock Performance - As of September 3, Hanyu Pharmaceutical's stock price decreased by 2.02%, trading at 26.16 CNY per share, with a total market capitalization of 23.106 billion CNY. The stock has increased by 102.95% year-to-date, with a 0.19% increase over the last five trading days, an 11.79% increase over the last 20 days, and a 53.88% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 4, where it recorded a net purchase of 545 million CNY [1]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical achieved a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to the parent company was 145 million CNY, showing a significant year-on-year increase of 1504.30% [2]. - The company has distributed a total of 417 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 9.95% to 63,000, with an average of 11,841 circulating shares per person, a decrease of 3.98% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3].

9月1日，安图生物盘中上涨2.02%，截至14:02，报41.39元/股，成交1.30亿元，换手率0.56%，总市值 236.51亿元。 资金流向方面，主力资金净流入331.24万元，特大单买入123.00万元，占比0.94%，卖出0.00元，占比 0.00%；大单买入2652.69万元，占比20.34%，卖出2444.44万元，占比18.75%。 安图生物今年以来股价跌2.34%，近5个交易日跌2.52%，近20日涨2.35%，近60日涨5.75%。 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营业务收入构成为：试剂86.63%，仪器10.99%，其他1.40%，维保收入0.98%。 安图生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：抗原检测、体外诊断、 猴痘概念、医疗器械、中盘等。 截至6月30日，安图生物股东户数3.42万，较上期增加0.04%；人均流通股16719股，较上期减少0.04%。 2025年1月-6月，安图生 ...

Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company was listed on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing industry [1]. Stock Performance - As of August 25, Hanyu Pharmaceutical's stock price increased by 2.05%, reaching 28.90 CNY per share, with a trading volume of 2.188 billion CNY and a turnover rate of 10.31%. The total market capitalization is 25.526 billion CNY [1]. - Year-to-date, Hanyu Pharmaceutical's stock price has risen by 124.20%. Over the past five trading days, the stock has decreased by 3.38%, while it has increased by 51.15% over the past 20 days and 102.24% over the past 60 days [1]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical achieved a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to shareholders was 145 million CNY, showing a significant year-on-year increase of 1504.30% [2]. - The company has distributed a total of 417 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders of Hanyu Pharmaceutical reached 63,000, an increase of 9.95% compared to the previous period. The average number of circulating shares per person is 11,841, which is a decrease of 3.98% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3]. Market Activity - Hanyu Pharmaceutical has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 4, where it recorded a net purchase of 545 million CNY. The total purchases amounted to 882 million CNY, accounting for 18.83% of the total trading volume, while total sales were 337 million CNY, accounting for 7.20% [1].